ABEO - Abeona Therapeutics Inc.
| Previous Close | 5.32 |
| Open | 5.35 |
| Bid | 5.15 x 900 |
| Ask | 5.22 x 1300 |
| Day's Range | 5.15 - 5.40 |
| 52 Week Range | 5.02 - 17.25 |
| Volume | 253,693 |
| Avg. Volume | 411,379 |
| Market Cap | 254.168M |
| Beta (3Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.13 |
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of ABEO earnings conference call or presentation 14-May-19 2:00pm GMT
Q1 2019 Abeona Therapeutics Inc Earnings Call
- GlobeNewswire•26 days ago
Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-202 for the treatment of CLN1 disease, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). ABO-202 is designed to deliver a functional copy of the PPT1 gene to cells of the central nervous system and peripheral organs using a combined intravenous and intrathecal delivery via the AAV9 vector.
Motley Fool•last monthAbeona Therapeutics Inc (ABEO) Q1 2019 Earnings Call Transcript
ABEO earnings call for the period ending March 31, 2019.
- GlobeNewswire•last month
Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed dosing cohort 1 and treated the first patient in cohort 2 in an ongoing Phase 1/2 clinical trial evaluating ABO-101, its novel one-time gene therapy for Sanfilippo syndrome type B (MPS IIIB). The Company expects to report interim data from the trial in the second half of 2019.
- Associated Press•last month
Abeona Therapeutics: 1Q Earnings Snapshot
The Dallas-based company said it had a loss of 39 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...
- GlobeNewswire•last month
Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced first quarter 2019 financial results and business highlights, which will be discussed on a conference call scheduled for Tuesday, May 14 at 10:00 a.m. ET. “We’ve had a great start to 2019, with continued progress across our pipeline, including the completion of CMC work in advance of initiating our Phase 3 VITAL™ clinical trial evaluating EB-101, our gene-corrected cell therapy for patients with recessive dystrophic epidermolysis bullosa,” said João Siffert, M.D., Chief Executive Officer. “We have continued to advance our lysosomal storage disease programs.
- GlobeNewswire•last month
Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID), being held May 8-11 in Chicago. As previously reported, these data showed that three years after treatment with EB-101, a majority of RDEB patients had durable wound healing. Notable improvements were also reported in outcomes associated with wound healing, including patient reported reductions in pain and itching.
- GlobeNewswire•last month
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
NEW YORK and CLEVELAND, May 07, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the.
- Zacks•last month
Earnings Preview: Abeona Therapeutics (ABEO) Q1 Earnings Expected to Decline
Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that intravitreal administration of the Company’s novel AIM™ AAV204 capsid to non-human primates led to robust transgene expression in the inner and outer retina. Findings were presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Vancouver.
- GlobeNewswire•2 months ago
Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today will report new preclinical data demonstrating that ABO-401, the Company’s novel gene therapy for cystic fibrosis (CF), efficiently delivered a highly-expressed, functional copy of human mini-CFTR (hCFTR) to the lung of CF mice and restored CFTR function in human CF patient nasal and bronchial epithelial cells. The data will be presented this evening at the American Society of Gene and Cell Therapy 22nd Annual Meeting in Washington, D.C. “These encouraging preclinical data add to the growing body of evidence suggesting ABO-401 may address the challenges in lung delivery and transgene expression that have limited the advancement of gene therapy for CF patients,” said Timothy J. Miller, Ph.D., President and Chief Scientific Officer.
- Simply Wall St.•2 months ago
Is Abeona Therapeutics's (NASDAQ:ABEO) 173% Share Price Increase Well Justified?
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does well. To wit, the Abeona...
- GlobeNewswire•2 months ago
Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
NEW YORK and CLEVELAND, April 15, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data.
- GlobeNewswire•2 months ago
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in cell and gene therapy development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABO-101, the Company’s novel one-time gene therapy for Sanfilippo syndrome type B (MPS IIIB). ABO-101 is designed to deliver a functional copy of the NAGLU gene to the central nervous system and peripheral tissues.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ABEO earnings conference call or presentation 19-Mar-19 2:00pm GMT
Q4 2018 Abeona Therapeutics Inc Earnings Call
Motley Fool•3 months agoAbeona Therapeutics Inc (ABEO) Q4 2018 Earnings Conference Call Transcript
ABEO earnings call for the period ending December 31, 2018.
- Associated Press•3 months ago
Abeona Therapeutics: 4Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•3 months ago
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. “The diligent work conducted over the past nine months at our GMP manufacturing facility puts us on track to initiate the pivotal VITAL™ study evaluating EB-101, our gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa, in mid-2019.
- Simply Wall St.•4 months ago
What Investors Should Know About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Financial Strength
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Zero-debt allows substantial financial flexibility, especially for small-cap companies likeRead More...
- GlobeNewswire•4 months ago
Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference
NEW YORK and CLEVELAND, Feb. 22, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies.
- GlobeNewswire•4 months ago
New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced the appointment of João Siffert, M.D. as Chief Executive Officer (CEO), effective immediately. Dr. Siffert joined Abeona as Head of Research & Development (R&D) and Chief Medical Officer (CMO) in 2018, and has served as interim CEO since November of last year.
- ACCESSWIRE•4 months ago
The Unknown Biotech Play that Could Deliver 400% Returns, or Much More
The market for cell therapies of all kinds is exploding in size. Orgenesis Inc (ORGS) is making a name for itself as a top-notch provider of manufacturing to cell therapy drug developers. The company's revenue is growing consistently, and they recently achieved a key milestone under a 2018 investment agreement from a leading healthcare investment groups in the U.S., Great Point Partners.
- GlobeNewswire•4 months ago
Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
NEW YORK and CLEVELAND, Jan. 31, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene.
- GlobeNewswire•5 months ago
Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer.
